SAB Biotherapeutics (NASDAQ:SABS) Issues Earnings Results, Beats Expectations By $0.44 EPS

Posted by Stuart Ham on May 11th, 2025

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.44, Zacks reports. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

SAB Biotherapeutics Price Performance

NASDAQ:SABS opened at $1.79 on Friday. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. The firm has a market cap of $16.63 million, a PE ratio of -0.48 and a beta of 0.47. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $5.01. The company’s 50-day moving average price is $1.49 and its two-hundred day moving average price is $2.55.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research report on Tuesday, April 1st. Chardan Capital lowered their price objective on SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SAB Biotherapeutics currently has an average rating of “Buy” and a consensus price target of $11.40.

Check Out Our Latest Stock Report on SAB Biotherapeutics

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.